Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
56.23
+1.54 (2.82%)
At close: Jun 26, 2026, 4:00 PM EDT
56.00
-0.23 (-0.41%)
After-hours: Jun 26, 2026, 7:57 PM EDT
Royalty Pharma Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Royalty Pharma stock have an average target of 59.43, with a low estimate of 50 and a high estimate of 66. The average target predicts an increase of 5.69% from the current stock price of 56.23.
Analyst Consensus: Buy
* Price targets were last updated on May 26, 2026.
Analyst Ratings
The average analyst rating for Royalty Pharma stock from 10 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 3 | 3 | 2 | 2 | 3 | 3 |
| Hold | 0 | 1 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 10 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citi | Citi | Buy Maintains $66 | Buy | Maintains | $66 | +17.38% | May 26, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $63 → $64 | Buy | Maintains | $63 → $64 | +13.82% | May 7, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $50 → $58 | Buy | Maintains | $50 → $58 | +3.15% | May 7, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains $54 → $62 | Buy | Maintains | $54 → $62 | +10.26% | May 7, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Reiterates $51 → $59 | Buy | Reiterates | $51 → $59 | +4.93% | May 7, 2026 |
Financial Forecast
Revenue This Year
3.43B
from 2.38B
Increased by 44.24%
Revenue Next Year
3.66B
from 3.43B
Increased by 6.67%
EPS This Year
5.12
from 4.83
Increased by 5.96%
EPS Next Year
5.61
from 5.12
Increased by 9.70%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 3.5B | 3.8B | |
| Avg | 3.4B | 3.7B | |
| Low | 3.3B | 3.5B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 47.7% | 10.3% | |
| Avg | 44.2% | 6.7% | |
| Low | 39.9% | 3.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 5.33 | 5.91 | |
| Avg | 5.12 | 5.61 | |
| Low | 4.62 | 5.19 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 10.4% | 15.4% | |
| Avg | 6.0% | 9.7% | |
| Low | -4.3% | 1.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.